Shanghai to strengthen oversight of imported medicines, medical devices
Shanghai has unveiled a plan to ensure drug safety and promote high-quality development in the pharmaceutical industry during the 15th Five-Year Plan period (2026-30).
The plan calls for strengthening the primary responsibility of overseas drug marketing authorization holders and medical device registrants for product quality, while clarifying the joint and several liability of domestic responsible persons for the quality and safety of imported drugs.
Shanghai will strengthen qualification reviews, capability assessments, and ongoing supervision of domestic responsible persons or agents. It will encourage closer alignment between their quality management systems and those of overseas marketing authorization holders or medical device registrants, ensuring that they fulfill their respective responsibilities for post-market studies, imports, storage and transportation, sales, traceability, recall management, pharmacovigilance monitoring, and annual reporting.
These measures will strengthen full life-cycle supervision and traceability of imported medicines and medical devices, while improving the standardization, transparency, and traceability of how domestic responsible persons or agents fulfill their obligations.
Shanghai will also support qualified domestic and overseas companies in segmented drug manufacturing and guide marketing authorization holders to establish unified quality assurance systems covering the entire manufacturing process and all production sites.
It will encourage the localization of manufacturing for overseas-produced medical devices already approved for the Chinese market, streamline procedures for production-site changes, and explore pilot programs to transfer medical device registration certificates. It will also support companies holding domestic medical device registration certificates in manufacturing Class II and Class III medical devices in Shanghai.
The plan also includes reforms to review and approval procedures for supplementary applications involving chemical drugs manufactured in China or overseas, as well as pre-submission support for applications involving major changes to chemical drugs in Shanghai.
Key drugs under development and imported drugs transferred to local production will receive priority for registration sampling and inspections. Registration verification and Good Manufacturing Practice compliance inspections will be conducted concurrently.
In addition, Shanghai will develop internationally aligned testing and inspection services for medicines and medical devices, support international multicenter clinical trials, and expand the scope of export sales certificates for medical devices.
The city will strengthen cooperation with international regulatory and certification bodies and promote greater alignment between domestic and international regulatory standards, helping locally developed medicines and medical devices reach overseas markets.
Source: Shanghai Food and Drug Safety Committee
FAQs
- Do I need a physical marriage certificate when applying for a residence permit for private affairs?
- Do I need to declare my ADHD medication to customs during an airside transit at Shanghai Pudong Airport?
- Is Wusongkou International Cruise Terminal an eligible port under the 240-hr visa-free transit policy?
- What are the customs and quarantine requirements for pets entering or leaving China via Shanghai Pudong airport?